Healthcare
Medicover AB (publ)(MCVEF)
Live Price
Offline$27.25
+0.00% today
1Y Change
+37.42%
Window
Jun 25, 2025 โ Jun 22, 2026
- Market Cap
- $2.90B
- Revenue Growth
- +13.7%
- EPS Growth
- +363.6%
- Dividend Yield
- 1.0%
Coverage: 254 bars ยท Jun 25, 2025 โ Jun 22, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Medicover AB (publ) (MCVEF) is a Healthcare stock with a market cap of $2.90B and listed on OTC. The stock last traded around $27.25 and up 37.4% across the available one-year price window (Jun 25, 2025 โ Jun 22, 2026). Baseline metrics include revenue growth of +13.7%, EPS growth of +363.6%, a dividend yield of 1.0%. What stands out right now is revenue +13.7%, EPS +363.6%, free cash flow +33.0% with operating margin 6.9% and ROIC 6.0%. The dividend is present but secondary, with a yield around 1.0%. Valuation already assumes a fairly strong business story at P/E 36.4 and price/sales 1.2. Stock Foundry combines MCVEF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+13.7% vs +7.6% peer median
Operating Margin
Below sector median
+6.9% vs +19.4% peer median
P/E
Near sector median
36.4 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Apr 29, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +13.7% and EPS at +363.6%, with operating margin around 6.9%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 1.0%, which matters if the thesis depends on income as much as growth.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged 0.0% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Apr 29, 2026 | โ | +0.0% | +0.0% | +0.0% |
2026 Feb 10, 2026 | +4.6% | +0.0% | +0.0% | +0.0% |
2025 Nov 5, 2025 | +12.2% | +0.0% | +0.0% | +0.0% |
Benchmark Edge
MCVEF vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
MCVEF
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
MCVEF Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for MCVEF and SPY.
Company Overview
Medicover AB (publ)
Other OTC
Medicover AB (publ) provides healthcare and diagnostic services in Germany, Sweden, Poland, Turkey, Belarus, Bulgaria, Georgia, Hungary, Serbia, Moldova, Ukraine, and India. It operates through two segment, Healthcare Services and Diagnostic Services. The company's diagnostic services comprise various tests, including allergy and autoimmune diagnostics, bacteriology, parasitology, biochemistry and immunochemistry, blood group diagnostics/transfusion medicine, tumour markers, clinical chemistry, cytology, haematology, histopathology, human genetics, hygiene, immunology and immunochemistry, infectious diseases, microbiology, molecular biology, and pharmacology/toxicology. The company operates 97 clinical laboratories, 733 blood-drawing points, and 26 clinics in 10 countries; and 117 medical clinics, 20 fertility clinics, 52 dental clinics, 25 hospitals, and 25 gyms. It serves corporate and private customers, and patients, as well as public payers. Medicover AB (publ) was founded in 1995 and is headquartered in Stockholm, Sweden.
- Leadership
- John Paul Stubbington
- IPO Date
- Aug 28, 2019
- Employees
- 47.0k
- Street Address
- P.O. Box 5283
- Mailing
- Stockholm, 102 46
- Region
- Stockholm, SE
- Reporting Currency
- USD
- Investor Line
- 46 8 40 01 76 00
- Last Updated
- May 2, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 36.4
- EV/EBITDA
- 11.0
- Price/Sales
- 1.2
- Price/Book
- 5.3
Growth
- Revenue
- +13.7%
- EPS
- +363.6%
- Free Cash Flow
- +33.0%
Profitability
- Gross Margin
- 23.3%
- Operating Margin
- 6.9%
- Net Margin
- 3.3%
- ROE
- 15.5%
- ROIC
- 6.0%
Balance Sheet
- Debt/Equity
- 2.60
- Current Ratio
- 0.74
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.